Performance

NTLA +27.21%

Watchlist

Select an item

RETURNS	1D	YTD	1Y	5Y Ann.	Max DD	Sharpe	Div. Yield
NTLA	+6.70%	+34.71%	+27.21%	-38.22%	-40.19%	0.64	0.00%

Summary

NTLA at a glance

NTLA returned +27.21% over the past year and -38.22% a year over five years. Its worst drop in that year was -40.19%, smaller than 37% of stocks on Redstone, and its Sharpe ratio of 0.64 beats 58% of stocks on Redstone. It pays no dividends.

Ranking

How NTLA ranks

Current Drawdown

-32.12%

Rolling Volatility

75.85%

Actions

Metrics

Risk Indicators

Alpha24.74%

Beta2.42x

Sharpe0.64

Sortino0.99

Omega1.11

Calmar0.68

Martin2.12

Profile

About NTLA

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics.

Sector: Health Care
Industry: In Vitro & in Vivo Diagnostic Substances
Market cap: $1.7B
Listed: May 2016
Employees: 377
Headquarters: Cambridge, MA
Website: intelliatx.com

Comparisons

NTLA: Intellia Therapeutics, Inc.

NTLA at a glance

How NTLA ranks

Current Drawdown

Rolling Volatility

About NTLA

Related comparisons